Abstract library

629 results for "Ono".
#2157 A Case Report of a Well-Differentiated Neuroendocrine Tumor in which Sunitinib Treatment Resulted an Effective Response of Disease
Introduction: A case report of no pancreatic well-differentiated neuroendocrine tumor in which sunitinib treatment resulted an effective response of disease
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: PH Radia Sai
Authors: SAI R
#779 Results of Pancreatic Surgery for Neuroendocrine Tumors: Single Center Experience with No Perioperative Mortality
Introduction: Pancreatic neuroendocrine tumors (p-NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: Dr Roberto Valente
Keywords: p-NET, surgery
#1587 LRIG1 Was Down-Regulated in Medullary Thyroid Cancer but No Significant Effect of LRIG1 Was Found in RET2B Transgenic Mice and Human Differentiated Thyroid Cancer
Introduction: There are four main types of thyroid cancer, papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic. In both PTC and MTC, genomic rearrangements and point mutations in the proto-oncogene RET are common. RET encodes a receptor tyrosine kinase that is negatively regulated by leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1). LRIG1 gene status and mRNA and protein expression correlate with patient survival in different types of cancer.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Associate profes David Lindquist
Keywords: LRIG1, RET, MTC
#1341 Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]-DOTATATE PET/CT
Introduction: Somatostatin receptor imaging with [68Ga]-DOTATATE PET/CT has become common practice in patients with NET. Current guidelines recommend discontinuing treatment with SSAs before obtaining a [68Ga]-DOTATATE PET/CT scan. The assumption is that unlabeled somatostatin may lower the detectability of lesions.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Else Aalbersberg
Keywords: DOTATATE
#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations
Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Maike Nieser
Keywords: NET
#1248 Case Report of Recurrent VIPoma
Introduction: 51yr presented with 7 month diarrhoea&2 stone weight loss. All tests negative, only abnormality hypokalaemia. FGH profile: VIP raised>400, peptide histidine methionine>1000, GAWK of 250. Diagnosis of VIPoma. CT: 5cm mass tail & body of pancreas, no hepatic or adrenal lesions. Octreotide treatment started. Bowel frequency improved, hypokalaemia corrected. Octreotide scan showed uptake only in pancreas. Patient readmitted 5 months later hypokalaemic myopathy, K 1.7, surgical distal pancreatectomy & splenectomy completed. Histology: NET within pancreas, moderate cellular differentiation, variable mitotic rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr Victoria Mulcahy
Authors: Mulcahy V, McStay M, Sizer B, ...
Keywords: VIPoma
#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Sara De Dosso
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#670 The Relationship Between the Ki-67 Protein and IGF-Related Genes in Gastroenteropancreatic Neuroendocrine Tumor Patients with Normal and Elevated Serum Chromogranin-A
Introduction: GEP-NETs are rare, heterogeneous neoplasms with a distinct biological and clinical behavior. Both IGF-system and Ki-67 indices have been reported as important stimulating factors in carcinogenesis and/or tumor progression. The tumor marker CgA is an independent predictor for survival as well. Currently no data are available about a possible interaction between IGF-system (IGF(-R)s, IRs, BPs) and Ki-67 protein in GEP-NET patients with normal and elevated serum CgA.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Drs Roxanne Van Adrichem
Keywords: GEP-NET
#1367 Thymic Neuroendocrine Neoplasia: Therapy with Everolimus
Introduction: Due to the low incidence of 0.02/100 000 no established medical therapy for thymic neuroendocrine neoplasia (t-NEN) exists.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. med. Matthias Lang
Authors: Lang M, Anamaterou C, ...